SOHO Italy

www.sohoitaly.it

 

1st School of Acute Leukemia
13:35

SOHO Italy 1st School of Acute Leukemia

The Road to AML: A Clinical and Biological Overview

FEATURING Sara Galimberti
  • 23 views
  • June 29, 2021
07:52

SOHO Italy 1st School of Acute Leukemia

AML Molecular Pathogenesis & Approach to Therapeutic Targets

FEATURING Sara Galimberti
  • 32 views
  • June 29, 2021
10:49

SOHO Italy 1st School of Acute Leukemia

FLT3m AML: Midostaurin + Chemo, Sorafenib Maintenance After Allo-HSCT, Aza+/-Ven for Newly Diagnosed Disease

FEATURING Giovanni Martinelli
  • 32 views
  • June 11, 2021
25:10

SOHO Italy 1st School of Acute Leukemia

AML in 2021: MD Anderson Perspective on Progress in Research and Therapy Options

FEATURING Hagop Kantarjian
  • 186 views
  • May 7, 2021
20:05

SOHO Italy 1st School of Acute Leukemia

Optimizing FLT3i Use in FLT3+ AML in 2021: What Are the Current and Future Therapeutics?

FEATURING Naval Daver
  • 139 views
  • May 4, 2021
  • 1
15:43

SOHO Italy 1st School of Acute Leukemia

2021 AML Drugs in EU: Microenvironment & Parasite Relations, Potentiating Apoptosis, Induction V-FLAI, Ivo or Gilteritinib+Ven in R/R, IMGN632, PARP1i, Ponatinib+/-Steroids

FEATURING Giovanni Martinelli
  • 10 views
  • April 15, 2021
16:03

SOHO Italy 1st School of Acute Leukemia

2021 Updates on the Role of Maintenance in AML: Stem Cell Modeling, IO (IL-2+Histamine, IFN Alpha, CPIs/Lenalidomide), Targeted Therapies (FLT3), HMAs

FEATURING Michele Gottardi
  • 111 views
  • April 15, 2021
  • 1
15:53

SOHO Italy 1st School of Acute Leukemia

Role of SCT in AML: Choice of Donor, HSCT in Active Disease, Older Pts & Comorbidities, GVL & GVHD, Maintenance/Salvage Strategies and Late Effects

FEATURING Attilio Olivieri
  • 86 views
  • April 15, 2021
14:48

SOHO Italy 1st School of Acute Leukemia

Environment-Mediated Drug Resistance in AML: Is Targeting CAMDR a New Frontier? What Is the Role of Uproleselan in Tumor Cells and Bone Marrow Microenvironment?

FEATURING Claudio Cerchione
  • 89 views
  • April 15, 2021
  • 1
09:40

SOHO Italy 1st School of Acute Leukemia

Role of Single Agent IDHi in AML: Effects on Hematopoiesis, Ena/Ivo for R/R Disease, Differentiation Syndrome, Molecular Remission

FEATURING Maria Paola Martelli
  • 5 views
  • April 15, 2021
05:02

SOHO Italy 1st School of Acute Leukemia

IDH1/2 Inhibitor Combinations for AML: Ivo/Ena+Aza for Newly Diagnosed Disease, Ivo+Ven+/-Aza for Adults, Ivo/Ena+Chemo

FEATURING Maria Paola Martelli
  • 107 views
  • April 15, 2021
  • 1
14:25

SOHO Italy 1st School of Acute Leukemia

2021 Updates on Ph+ ALL: Chemo+Dasatinib, Dasatinib vs. Imatinib in Pediatric Disease, Hyper-CVAD Combos, Blina+InO/Dasatinib/Ponatinib, InO+Bosutinib, Ponatinib+Venetoclax

FEATURING Elias Jabbour
  • 31 views
  • April 15, 2021
12:15

SOHO Italy 1st School of Acute Leukemia

Integrating IO in the Frontline ALL: Hyper-CVAD+Ponatinib, Blina+Ino, Dasatinib+Blina, Chemo Rx+/- Rituximab, HCVAD Combos, MRD & NGS

FEATURING Elias Jabbour
  • 134 views
  • April 15, 2021
  • 1
16:56

SOHO Italy 1st School of Acute Leukemia

Novel Antibodies in AML: What Is the Role of Gemtuzumab Ozogamicin? Do Bispecific Antibodies Show Activity? What Is the Role of CPIs?

FEATURING Farhad Ravandi
  • 197 views
  • April 14, 2021
  • 2
16:41

SOHO Italy 1st School of Acute Leukemia

AML Management: Strategies to Integrate IO & Targeted Therapies

FEATURING Naval Daver
  • 259 views
  • April 14, 2021
  • 2
13:23

SOHO Italy 1st School of Acute Leukemia

CAR-T Based Approach in ALL: Humanized CAR-T, Fast-Off Rate Low-Affinity CAR-T 19, CAR-T 22, Dual CAR-T, CAR-T for T-ALL & NK-CAR

FEATURING Josep-Maria Ribera
  • 15 views
  • April 14, 2021
07:44

SOHO Italy 1st School of Acute Leukemia

How Do I Manage Ph-Like ALL at MD Anderson: HCVAD + Ofatumumab, Testing Algorithm, TKI Trials, New mAb Drugs, alloSCT, and Current Clinical Practice

FEATURING Marina Konopleva
  • 140 views
  • April 14, 2021
  • 1
05:05

SOHO Italy 1st School of Acute Leukemia

How Do I Manage ETP ALL at MD Anderson: Hyper-CVAD + Nelarabine, Hyper-CVD + Ven, Navitoclax, Ven & Low-Dose Chemo, Treatment Strategies

FEATURING Marina Konopleva
  • 165 views
  • April 14, 2021
24:35

SOHO Italy 1st School of Acute Leukemia

CD19 Cells in Childhood & Adult ALL Relapsed After ASCT: Anti-CD19 CAR-T for High-Risk B-ALL, Donor-Derived SB CARCIK-CD19 in B-ALL

FEATURING Alessandro Rambaldi
  • 4 views
  • April 13, 2021
20:15

SOHO Italy 1st School of Acute Leukemia

Role of mAbs in R/R ALL: INO vs. SoC, INO for B-Cell Disease Eligible for HSCT, Blina vs. Chemo in Younger Patients

FEATURING Francesco Lanza
  • 4 views
  • April 13, 2021
14:08

SOHO Italy 1st School of Acute Leukemia

2021 ALL Updates: Disease Identification Markers, INO vs. SoC in R/R Disease, Blina vs. Chemo for R/R Pre-B Patients, INO for Adults With MRD+ B-Cell Disease Prior to HSCT

FEATURING Giovanni Martinelli
  • 48 views
  • April 13, 2021
21:41

SOHO Italy 1st School of Acute Leukemia

2021 Updates on MRD Assessment and Impact on AML: MRD Monitoring, ELN Effort, Treatment Allocation, ASCT Benefit, Strategies to Prevent Relapse

FEATURING Francesco Buccisano
  • 2 views
  • April 13, 2021
19:42

SOHO Italy 1st School of Acute Leukemia

How I Manage ALL in 2021: Can Adult Ph+ Patients Achieve CMR With Dasatinib-Blina Combo in Frontline Setting? Is OS Improved With INO vs. SoC in R/R Disease?

FEATURING Giovanni Martinelli
  • 7 views
  • April 13, 2021
26:39

SOHO Italy 1st School of Acute Leukemia

2021 MD Anderson Updates on ALL: Treatment Comparison by Age and Disease Type, Survival Differences

FEATURING Hagop Kantarjian
  • 117 views
  • April 13, 2021